Table 3.

Risk of incidence of all types of fractures as a function of phosphate levels in RS-I, RS-II and MrOS

	Model I			Model II
	nofxs/total n	HR1,2 (95% CI)	p	nofxs/total n	HR1,2 (95% CI)	p
RS-I
Men	152/1476	1.95 (1.37–2.77)	<0.001	116/1094	1.74 (1.12–2.69)	0.013
Women	390/1828	1.33 (1.05–1.69)	0.017	279/1325	1.48 (1.11–1.97)	0.007
Sex-combined	542/3304	1.50 (1.23–1.83)	<0.001	395/2419	1.54 (1.21–1.95)	<0.001
RS-II
Men	75/1127	1.33 (0.78–2.25)	0.292	51/876	1.58 (0.84–2.95)	0.153
Women	162/1356	0.90 (0.62–1.31)	0.583	116/1012	1.02 (0.66–1.56)	0.937
Sex-combined	237/2483	1.03 (0.76–1.40)	0.829	167/1888	1.18 (0.83–1.69)	0.351
RScombined2
Men	227/2603	1.73 (1.29–2.32)	<0.001	167/1970	1.69 (1.18–2.41)	0.004
Women	552/3184	1.19 (0.97–1.45)	0.092	395/2337	1.32 (1.04–1.67)	0.023
MrOS
Men	1046/5409	1.54 (1.34–1.77)	<0.001	1046/5409	1.50 (1.30–1.72)	<0.001
Studies combined3
Men	1273/8012	1.57 (1.39–1.78)	<0.001	1213/7379	1.52 (1.34–1.74)	<0.001
Women	552/3184	1.19 (0.97–1.45)	0.092	395/2337	1.32 (1.04–1.67)	0.023
Sex-combined	1825/11196	1.45 (1.31–1.62)	<0.001	1608/9716	1.47 (1.31–1.65)	<0.001

n_o fxs: number of fractures

Model I: age, BMI and smoking adjusted; additional race and site adjustments in MrOS

Model II: adjusted for age, BMI, smoking, FN-BMD, alcohol intake, prevalent diabetes mellitus, prevalent cardiovascular disease, eGFR and serum levels of potassium, and calcium; additional adjustments for season-adjusted 25(OH)D in RS cohorts and race and site adjustments in MrOS

¹.Hazard ratios are expressed per increase in 1 mg/dL of P levels.

²HRs from Cox models

³.Studies combined applying a fixed effects model